logo-loader
viewBioDiem

BioDiem advances development of fungal disease treatment

au_microscope350_518c41fd96835.jpg

BioDiem’s (ASX: BDM) novel antimicrobial, BDM-I, has moved into the preclinical animal studies phase to assess its potential as a treatment for the fungal disease, pneumocystosis.

BDM-I is a synthetic compound targeting the treatment of serious human infections, while pneumocystis is a difficult-to-treat fungus that can cause serious pneumonia in the aged and infants, as well as those who are ill or have a weakened immune system.

Two new studies will be conducted under the U.S. National Institute of Allergy and Infectious Diseases’ (NIAID) preclinical services program, which earlier assessed BDM-I’s effectiveness in vitro against 70 different strains of opportunistic or hospital-acquired fungi with significant medical need for better treatments.

This earlier data showed that BDM-I had significant activity against infection caused by the organism, pneumocystis spp.

The new study will involve NIAID’s Animal Models of Infectious Disease Program, where a NIAID-funded contractor will conduct studies in a mouse model of pneumocystis infection to assess both optimal dose and overall effectiveness of BDM-I as a novel treatment.


Pneumocystis prevalence


Pneumocystis is a yeast-like fungus that many healthy people carry without symptoms.

However, in patients with a suppressed or compromised immune system, such as cancer patients and particularly HIV patients, it is very problematic causing pneumonia which is a major cause of death in patients who do not have preventative treatment.

In the U.S., the incidence of pneumocystis pneumonia is estimated to be 9% among hospitalised HIV/AIDS patients and 1% among solid organ transplant recipients.

In immuno-compromised patients, the mortality rate ranges from 5% to 40% in those who receive treatment. The mortality rate approaches 100% without therapy.


Outlicensing


BDM-I is in the preclinical stage with out-licensing the planned outcome of the antimicrobial’s development.

Patent applications for BDM-I have been granted in China, Russia, Singapore and Australia, as well as in three of the world’s largest patent jurisdictions – Europe, Japan and the U.S.




Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: BioDiem

Price: - -

ASX:BDM
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Delecta hones in on Copper Ridge in Utah and outlines exploration steps

Delecta Limited (ASX:DLC) technical director Greg Smith updates Proactive on the newly acquired Copper Ridge project in Utah, USA, and next steps in the exploration program.  The Copper Ridge acquisition covers four historical copper mines and prospects. Delecta's acquisition also...

44 minutes ago

2 min read